News >

Frontline Pembrolizumab Combo Approved in Europe for Nonsquamous NSCLC

Jason M. Broderick @jasoncology
Published: Monday, Sep 10, 2018

Roger M. Perlmutter, MD, PhD

Roger M. Perlmutter, MD, PhD
The European Commission has approved frontline pembrolizumab (Keytruda) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) without EGFR or ALK mutations.

 <.00001).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x